Should you be interested in the study participation, please, contact us at: rberkovich.research@gmail.com
Current Enrolling Studies
FREXALT (Open to Enrollment):
Phase 3 Study of Frexalimab in Relapsing Multiple Sclerosis
Protocol # EFC 17919
Site: 8400005
Sponsor: Sanofi
ClinicalTrials.gov Identifier: NCT06141473
FREVIVA (Open to Enrollment):
Phase 3 Study of Frexalimab in Progressive Multiple Sclerosis
Protocol # EFC 17504
Site: 8400005
Sponsor: Sanofi
ClinicalTrials.gov Identifier: NCT06141486
REMODEL (Open to Enrollment):
Phase 3 Study of Remibrutinib in Relapsing Multiple Sclerosis
Protocol # CLOU064C12302
Site: 5064
Sponsor: Novartis
ClinicalTrials.gov Identifier: NCT05156281
Ongoing Studies (enrollment closed)
EVOLUTION
Phase 3 Study of Evobrutinib in Relapsing Multiple Sclerosis
Protocol # MS200527_0082
Site: 737
Sponsor: EMD Serono Research & Development Institute, Inc.
ClinicalTrials.gov Identifier: NCT04338061
HERCULES
Phase 3 Study of Tolebrutinib in Relapsing Multiple Sclerosis
Protocol # EFC16645
Site: 8400059
Sponsor: Sanofi
ClinicalTrials.gov Identifier: NCT04411641
AGNOS
Phase 4 Study of Ofatumumab in Relapsing Multiple Sclerosis
Protocol # COMB157GUS10
Site: 1003
Sponsor: Novartis
ClinicalTrials.gov Identifier: NCT05084638
MASTER-2
Phase 4 Study of Cladribine in Relapsing Multiple Sclerosis
Protocol # MS700568_0079
Site: 954
Sponsor: EMD Serono, Inc.
ClinicalTrials.gov Identifier: NCT03933202